Fortis Healthcare Ltd Q4 FY25 Earnings Analysis

- Hospital business expects medium-term revenue growth of around 14%-15% year-on-year, driven by ~5%-6% ARPOB growth and bed expansion alongside better utilization of existing capacity (Page 11). - Brownfield bed expansion planned at around 350-400 beds per year over the next couple of years, with enough opportunities to add 1,000+ beds beyond FY'26 on a brownfield basis (Page 12). - Diagnostic business anticipates achieving industry-level growth of 8%-10% by Q2-Q3 of next fiscal year, driven largely by volume growth rather than price increases (Page 12). - Specialty services like Oncology, Neurosciences, and robotic surgeries are key contributors to strong ARPOB and volume growth (Page 4 and 7). - International patient revenue remains stable with growth seen primarily in Central Asia, Middle East, and Africa; Bangladesh contribution is currently small (Page 11). - Digital channel revenues are growing robustly, contributing nearly 30% to hospital revenues, supporting overall volume expansion (Page 4).

- Fortis Healthcare targets EBITDA margin expansion from the current ~20.5% to 25% in the near future. - Hospital business revenue growth guidance is around 14-15% year-on-year, driven by 5-6% ARPOB (Average Revenue Per Occupied Bed) growth plus volume and bed expansion. - Diagnostic business anticipates returning to industry-level growth (~8-10%) by Q2 or Q3 FY '26, mainly through volume growth rather than price increases. - New greenfield facility at Manesar is expected to breakeven at EBITDA level by Q1 FY '26 (June-September quarter). - Continued brownfield expansions expected to add approximately 350-400 beds per year over the next couple of years. - Company aims for sustained improvement in profitability with debt under control and margins improving through better occupancy and operational efficiencies.

- Total capex for the year is around INR 900 crore. - This includes approximately INR 600 crore for brownfield expansion projects. - INR 300 crore is earmarked for maintenance capex. - The main expansion focus is on brownfield projects; Manesar is the only greenfield project in the next 2-3 years. - Fortis is actively evaluating acquisition opportunities and land purchases in certain high-potential areas as part of a strategic, value-driven approach. - No specific timeline or number of acquisitions announced, as expansion is opportunistic. - Rebranding expenses for the Diagnostics business (Agilus) are expected to largely end by Q4 FY25 with no major one-off expenses planned next year. - Continued focus on expanding bed capacity by 350-400 beds annually, primarily through brownfield expansions.

- In December 2024, Fortis Healthcare successfully raised INR 1,550 crores through issuance of non-convertible debentures (debt). - These funds, along with internal accruals, were used to consolidate their stake in Agilus by acquiring 31.52% stake from private equity investors, increasing their holding to 89.2%. - No specific mention of any upcoming or planned new fundraising through debt or equity beyond this. - The company currently has a net debt of INR 644 crores as of December 31, 2024, and a net debt-to-EBITDA ratio of 0.41x. - Management did not provide explicit guidance on future fundraising, focusing instead on operational performance and expansions.

The transcript from the Fortis Healthcare Limited Q3 FY '25 earnings call does not explicitly mention details about the company's current or expected order book or pending orders. However, insights related to expansion and operational plans include: - The Manesar greenfield facility was operationalized in the current quarter, booking an opex loss of INR 12-13 crores, expected to breakeven by Q1 FY '26. - Brownfield bed expansions are ongoing, with around 350 to 400 beds expected to be added annually. - Opportunities exist to add approximately 1,000 beds on a brownfield basis beyond FY '26. - Capex guidance: INR 900 crore for the year (INR 600 crore for expansion and INR 300 crore for maintenance). - Management is actively evaluating acquisitions and land acquisitions to expand, but no specific deals or order book values disclosed. No specific numerical orderbook or pending orders data was provided in the document.